THE WIRE · № 76199
E2 Secures Dual FDA Clearances for the Hēlo® Platform, Introducing a PE Thrombectomy System with Integrated Blood Return
01 THE MACHINE READ
WHY IT MATTERS.
FDA clearances for a thrombectomy platform expand treatment options, a positive for the device maker though privately held.
Device approval adds competition in vascular thrombectomy niche
Commercial rollout and hospital adoption
Private company, limited public-market read-through
FULL DISPATCH
Combination of Hēlo Thrombectomy System and Hēlo Return establish the first 510(k)-cleared platform compatible with continuous vacuum aspiration MENLO PARK, Calif., Oct. 12, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease2026-10-12 18:02 UTC
Is Picard Medical (NYSEAMERICAN:PMI) Overbought After a 12.87% Gain and an RSI of 74.6?2026-10-12 18:05 UTC
Interim Real-World Results Show At-Home Subcutaneous Furosemide Can Effectively Treat Worsening Heart Failure in Patients at Imminent Risk for Hospital Admission2026-10-12 18:30 UTC
Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)2026-10-12 18:43 UTC
Immorta Bio Pioneers AI-Designed Senolytic Immunotherapy Targeting Diseases of Aging2026-10-12 13:22 UTC
Plasma Fractionation Market worth $52.58 billion by 20312026-10-12 14:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.